For months, Crescendo Therapeutics appears to have been thumbing its corporate nose at the FDA. Last November, the agency warned the little company for failing to maintain a system for collecting adverse event reports for its HybriSil topical treatment for scars. Crescendo offered a novel explanation – side effect reports simply had not been received (back story). Moreover, the FDA upbraided Crescendo for marketing HybriSil in the first place – the product, you see, was never approved.
